<?xml version="1.0" encoding="UTF-8"?>
<p id="p0110">Hydroxychloroquine penetrates the central nervous system. Patients with glioblastoma were safely treated with HCQ (600Â mg/day) used in conjunction with radiation and adjuvants [
 <xref rid="bb0130" ref-type="bibr">26</xref>]. The correlation between brain and plasma concentrations showed a 4 to 30-fold difference for HCQ, demonstrating its ability to diffuse in the brain [
 <xref rid="bb0135" ref-type="bibr">27</xref>]. Based on this observation, hydroxychloroquine may reach antiviral concentrations in the brain, leading to an expected preventive effect on early symptoms such as anosmia, which may persist after recovery from COVID-19.
</p>
